Filing Overview
This Form 6-K was filed by I-MAB, a Cayman Islands exempted company and foreign private issuer, for September 2020. The filing date was September 4, 2020. The request metadata identifies the company as Novabridge Biosciences, but the filing itself identifies the registrant as I-MAB.
Business Context and Material Transaction
On September 3, 2020, I-MAB entered into a global strategic partnership with AbbVie Ireland Unlimited Company for lemzoparlimab, also known as TJC4, an anti-CD47 monoclonal antibody for potential cancer treatment.
- I-MAB granted AbbVie worldwide development and commercialization rights outside Mainland China, Macau, and Hong Kong.
- I-MAB retained rights in Mainland China, Macau, and Hong Kong.
- The companies will collaborate on global clinical trials and may pursue additional CD47-related therapies, including bispecific antibodies and combination therapies with venetoclax.
- AbbVie will be the primary manufacturer for global supply, while the parties will share manufacturing responsibilities.
Financial and Operating Metrics
- Upfront payment: US$180 million.
- Initial clinical milestone payment: US$20 million, related to recently released topline clinical data.
- Combined upfront and initial milestone payments: US$200 million.
- Additional potential development, regulatory, and sales milestones for lemzoparlimab: up to US$1.74 billion, including US$840 million tied to clinical development and regulatory approvals.
- Royalties: tiered royalties in the low-to-mid teen percentages on global net sales outside Greater China, upon commercialization.
- AbbVie has a right of first negotiation for two additional lemzoparlimab-based bispecific antibody programs. Each could have at least US$500 million of upfront and milestone payments, or at least US$1 billion in aggregate, subject to further agreement.
- The filing does not provide revenue, net income, cash flow, cash balance, margins, debt, liquidity, or balance-sheet figures.
Clinical Data and Outlook
I-MAB reported topline results from a Phase 1 trial indicating that lemzoparlimab was well tolerated as a single agent at doses up to 30 mg/kg without a priming dose. Among dose-limiting-toxicity-evaluable patients, the company reported no dose-limiting toxicities or severe hematologic adverse events. Full data were expected to be presented at a scientific conference later in 2020.
The company stated that the partnership could accelerate the establishment of commercial production operations in China. Future value remains dependent on clinical development, regulatory approvals, commercialization, achievement of milestones, and any subsequent licensing agreements.
Risks and Contingencies
- Clinical results may not confirm safety or efficacy or support continued development.
- Regulators may delay or deny approvals, and the timing and content of regulatory decisions remain uncertain.
- Commercial success is not assured if lemzoparlimab is approved.
- Milestone payments and potential bispecific antibody payments are contingent on future events and agreements.
- I-MAB relies on third parties for drug development, manufacturing, and other services.
- The company cited its limited operating history, potential need for additional funding, intellectual-property risks, and the impact of COVID-19 on clinical, commercial, and other operations.
Investor Verification Items
- Verify receipt, accounting treatment, and timing of the US$200 million in upfront and initial milestone payments.
- Review the complete AbbVie agreement for milestone conditions, royalty terms, territorial rights, manufacturing obligations, and termination provisions.
- Confirm the clinical dataset underlying the Phase 1 topline results and review the subsequent full conference presentation.
- Assess whether additional milestone payments were achieved and whether the two potential bispecific antibody licenses were pursued.
- Review I-MAB’s latest financial statements for cash, liquidity, operating losses, financing needs, and the impact of the transaction.